Myriad Genetics, founded in 1991, is a genetic testing and precision medicine company that has performed millions of genetic tests over more than 30 years. This large-scale data generation places the company within sectors where computational analysis, including approaches from data science and machine learning, is integral to interpreting genomic information.
The company's technical domains encompass molecular diagnostics, genomics, and precision medicine. Its products, such as the myRisk Hereditary Cancer Test, myChoice CDx companion diagnostic for ovarian cancer, GeneSight for mental health medication selection, and prenatal screening tests, involve analyzing genetic data to guide personalized healthcare decisions.
Operating in industry verticals like healthcare, oncology, and mental health, Myriad Genetics' work in advancing molecular diagnostics aligns with fields where artificial intelligence is applied to improve diagnostic accuracy and treatment personalization.
